Alternative data datasets
Browse by provider, category, marketplace, access, delivery and license
Over twenty million adverse event reports covering drugs and medical devices are consolidated, refreshed daily, and structured for analysis.
Normalized extracts from the FDA FAERS system enable evaluation of drug adverse event reports and related safety signals.
Structured records of FDA medical device adverse event reports, formatted to support safety monitoring and risk evaluation workflows.
Three decades of measurements covering heavy metals, pesticide residues, and nutritional content in roughly 280 food items available in the United States, prepped for analysis.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
View source information and access options.
FDA-regulated products and events exposed as structured JSON: adverse drug-event reports, device recalls and registrations, labels, the NDC directory and food enforcement, used for pharmacovigilance and regulatory-risk screens.
Extensive United States pharmaceutical reference data is available to support regulatory, clinical safety, and research workflows.
View source information and access options.
Tracks FDAAA Section 801 reporting adherence, ranks sponsor credibility, and surfaces trial-level risk signals.
Pharmacovigilance risk assessment scores tied to biological mechanisms, derived from FDA prescribing information, published research, and ongoing clinical studies.
A 10% sample of over 573,000 ClinicalTrials.gov studies augmented with AI-classified therapeutic areas, sponsor categorization, outcome groupings, and duration metrics, offered for portfolio and market landscape analysis.
Over 635,000 registered clinical studies from ClinicalTrials.gov together with a supplementary pharma intelligence table of roughly 1.06 million rows that map those trials to FDA drug approvals, distributed as part of an open data initiative for academic and personal use.